REACT: A phase II study of rindopepimut (CDX-110) plus bevacizumab (BV) in relapsed glioblastoma (GB)

MLA

Thomas A. Davis, et al. “REACT: A Phase II Study of Rindopepimut (CDX-110) plus Bevacizumab (BV) in Relapsed Glioblastoma (GB).” Journal of Clinical Oncology, vol. 30, May 2012, p. TPS2103. EBSCOhost, https://doi.org/10.1200/jco.2012.30.15_suppl.tps2103.

APA

Thomas A. Davis, Jennifer Green, John H. Sampson, Olivier Rixe, Erin M. Dunbar, James J. Vredenburgh, Ronald G. Steis, Annick Desjardins, David A. Reardon, & Nitin B. Chandramouli. (2012). REACT: A phase II study of rindopepimut (CDX-110) plus bevacizumab (BV) in relapsed glioblastoma (GB). Journal of Clinical Oncology, 30, TPS2103. https://doi.org/10.1200/jco.2012.30.15_suppl.tps2103

Chicago

Thomas A. Davis, Jennifer Green, John H. Sampson, Olivier Rixe, Erin M. Dunbar, James J. Vredenburgh, Ronald G. Steis, Annick Desjardins, David A. Reardon, and Nitin B. Chandramouli. 2012. “REACT: A Phase II Study of Rindopepimut (CDX-110) plus Bevacizumab (BV) in Relapsed Glioblastoma (GB).” Journal of Clinical Oncology 30 (May): TPS2103. doi:10.1200/jco.2012.30.15_suppl.tps2103.